Cobicistat - Open Access .click

Results 41 to 50 of about 4,498 (182)

SARS‐CoV‐2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV

Journal of Medical Virology, Volume 98, Issue 8, August 2026.
ABSTRACT This study examined changes in anti‐Spike (anti‐S) antibodies (Abs) and type I interferon (IFN‐I) following the BNT162b2 vaccine in people living with HIV (PLWH) and analyzed the impact of demographic and immunological factors. In total, 75 PLWH and 28 healthy donors were followed at baseline (T0), at the second dose (T1), after the second ...
Federica Frasca +18 more
wiley +1 more source

Aspectos farmacológicos de darunavir/cobicistat

Enfermedades Infecciosas y Microbiología Clínica, 2016
Rezolsta® (darunavir/cobicistat) es el primer inhibidor de la proteasa potenciado en combinación fija con un nuevo potenciador farmacológico. Darunavir es actualmente el inhibidor de la proteasa de uso preferente con un perfil de eficacia y seguridad bien conocido.
González-Doménech, Carmen María +2 more
openaire +3 more sources

Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in Japan

Hepatology Research, Volume 56, Issue 8, Page 1202-1212, August 2026.
ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi +6 more
wiley +1 more source

Targeting MEST using cobicistat as a therapeutic strategy for gastric cancer through suppressing NF-κB signaling

Frontiers in Oncology
BackgroundGastric cancer (GC) constitutes a substantial global public health challenge, and the lack of tractable molecular targets limits therapeutic progress.
Hongtai Cao +14 more
doaj +1 more source

A multidisciplinary, AI‐supported quality improvement intervention to manage polypharmacy in aging people with HIV

HIV Medicine, Volume 27, Issue 7, Page 1109-1119, July 2026.
Abstract Objectives Aging people with HIV are increasingly affected by multimorbidity and polypharmacy, which heighten the risk of drug–drug interactions (DDIs) and potentially inappropriate medications (PIMs). This study evaluated a multidisciplinary, AI‐supported quality improvement intervention designed to optimize polypharmacy management in older ...
Jovana Milic +13 more
wiley +1 more source

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, Volume 27, Issue 5, Page 727-739, May 2026.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito +13 more
wiley +1 more source

Effectiveness and Persistence of Long‐Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort

Journal of the International AIDS Society, Volume 29, Issue 4, April 2026.
ABSTRACT Introduction Migrants living with HIV often face high mobility, vulnerability and limited baseline information on HIV‐1 genotype or treatment history. We aimed to assess the effectiveness and persistence of long‐acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) among migrants in Spain. Methods This multicentre cohort study across 58
Jara Llenas‐García +62 more
wiley +1 more source

Immunocompromised Status Definition in Observational Studies Using Electronic Health Records: A Scoping Review and a Proposal for a Phenotype Identification Algorithm

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 4, April 2026.
ABSTRACT Immunocompromised individuals experience an impaired immune function due to conditions that might be either congenital or acquired over the course of their lives. Epidemiological studies often rely on clinical definitions which, in some cases, benefit from being translated into machine‐readable algorithms for application to electronic health ...
Judit Riera‐Arnau +62 more
wiley +1 more source

HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study

AIDS Research and Therapy, 2017
Background As a simplification strategy for treatment-experienced HIV-infected patients who have achieved virologic suppression on a multi-drug, multi-class antiretroviral regimen, the aim of this study was to evaluate the safety, efficacy, and ...
Marianne Harris +5 more
doaj +1 more source

Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism

Drugs in R&D, 2023
Background and Objective Esmethadone (dextromethadone; d-methadone; S-methadone (+)-methadone; REL-1017) is the opioid inactive dextro-isomer of racemic methadone.
Nicola Ferri +10 more
doaj +1 more source

darunavir
ritonavir
hiv

covid-19
antiretroviral therapy
infectious and parasitic diseases

medicine
sars-cov-2
pharmacology